Citalopram side effects: what 136,022 FDA adverse event reports show
Drug class
Selective serotonin reuptake inhibitor (ssri)
Who reports
136,022 reports · 77% serious · 18,996 with death outcome · 67% female
Used for
Citalopram tablets are indicated for the treatment of major depressive disorder (MDD) in adults . Citalopram is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder (MDD) in adults ( 1 ) .
What it is
Citalopram tablets, USP contain citalopram, a selective serotonin reuptake inhibitor (SSRI). Citalopram hydrobromide is a racemic bicyclic phthalane structure and is designated (±)-1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3dihydroisobenzofuran-5-carbonitrile hydrobromide with the following structural formula:
Boxed warning
SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short- term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )] .
Causality screen of the 40 strongest signals
What the badges mean
- Labeled — boxed warning The term (or its clinical synonym) appears in the FDA boxed warning: causality is regulator-recognised and considered serious.
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Outcome field, not a reaction Death is a report outcome, not a reaction term. It is dominated by the underlying illness; see the seriousness profile and the boxed warning instead.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,127 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Temperature regulation disorder | 556 | 52.5 47.7–57.8ROR 52.7 · calibrated p 1e-5 ✓ | 39.2 EB05 36.5 · IC025 +5.1 3/3 methods agree | Not in label — unassessed | serious n=553 · ♀ 91% (drug 67%) | no trial arm names this drug |
| Antipsychotic drug level below therapeutic | 172 | 50.6 42.6–60.1ROR 50.6 · calibrated p 1e-5 ✓ | 38.0 EB05 33.5 · IC025 +4.9 3/3 methods agree | Lab value / disease marker | serious n=171 · ♀ 0% (drug 67%) · 100% clinician | no trial arm names this drug |
| Agitation neonatal | 130 | 24.2 20.1–29.1ROR 24.2 · calibrated p 9e-4 ✓ | 21.0 EB05 18.1 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=128 · ♀ 0% (drug 67%) · 100% clinician | no trial arm names this drug |
| Disinhibition | 216 | 23.7 20.6–27.4ROR 23.8 · calibrated p 9e-4 ✓ | 20.6 EB05 18.4 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=216 · ♀ 0% (drug 67%) | no trial arm names this drug |
| Respiratory disorder neonatal | 204 | 22.6 19.5–26.1ROR 22.6 · calibrated p 0.001 ✓ | 19.7 EB05 17.6 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=204 · ♀ 0% (drug 67%) | no trial arm names this drug |
| Steroid dependence | 105 | 21.6 17.6–26.5ROR 21.6 · calibrated p 0.002 ✓ | 19.0 EB05 16.1 · IC025 +3.8 3/3 methods agree | Labeled (related wording) related wording | serious n=105 · ♀ 0% (drug 67%) · 100% clinician | no trial arm names this drug |
| Catarrh | 102 | 19.9 16.2–24.4ROR 19.9 · calibrated p 0.002 ✓ | 17.6 EB05 14.9 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=102 · ♀ 0% (drug 67%) · 100% clinician | no trial arm names this drug |
| Psychiatric decompensation | 191 | 16.6 14.3–19.3ROR 16.7 · calibrated p 0.005 ✓ | 15.1 EB05 13.3 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=191 · ♀ 0% (drug 67%) · 100% clinician | no trial arm names this drug |
| Anorgasmia | 244 | 15.1 13.2–17.2ROR 15.1 · calibrated p 0.007 ✓ | 13.8 EB05 12.4 · IC025 +3.5 3/3 methods agree | Labeled adverse reaction exact term | serious n=229 | no trial arm names this drug |
| Accidental death | 153 | 13.8 11.7–16.3ROR 13.8 · calibrated p 0.010 ✓ | 12.7 EB05 11.0 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious n=153 · 100% clinician | no trial arm names this drug |
| Food allergy | 602 | 13.3 12.2–14.4ROR 13.3 · calibrated p 0.011 ✓ | 12.3 EB05 11.5 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious n=590 · ♀ 100% (drug 67%) | no trial arm names this drug |
| Serotonin syndrome | 1,513 | 13.2 12.5–13.9ROR 13.3 · calibrated p 0.011 ✓ | 12.2 EB05 11.7 · IC025 +3.5 3/3 methods agree | Labeled — boxed warning exact term | age-adj. PRR 11.5 · serious PRR 9.1 | no trial arm names this drug |
| Tearfulness | 312 | 11.9 10.6–13.4ROR 11.9 · calibrated p 0.017 ✓ | 11.1 EB05 10.1 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious n=288 · ♀ 43% (drug 67%) | no trial arm names this drug |
| Depressive symptom | 250 | 11.7 10.3–13.4ROR 11.8 · calibrated p 0.019 ✓ | 10.9 EB05 9.8 · IC025 +3.2 3/3 methods agree | Labeled (related wording) related wording | serious n=239 · ♀ 0% (drug 67%) | no trial arm names this drug |
| Depression suicidal | 239 | 11.4 10.0–13.0ROR 11.4 · calibrated p 0.021 ✓ | 10.6 EB05 9.5 · IC025 +3.2 3/3 methods agree | Labeled (related wording) related wording | serious n=238 · ♀ 32% (drug 67%) | no trial arm names this drug |
| Alcohol poisoning | 183 | 11.4 9.8–13.2ROR 11.4 · calibrated p 0.021 ✓ | 10.5 EB05 9.3 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious n=181 · ♀ 39% (drug 67%) · 100% clinician | no trial arm names this drug |
| Psychomotor skills impaired | 172 | 10.7 9.2–12.5ROR 10.7 · calibrated p 0.026 ✓ | 10.0 EB05 8.8 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=171 · ♀ 0% (drug 67%) · 100% clinician | no trial arm names this drug |
| Burns second degree | 113 | 10.6 8.7–12.8ROR 10.6 · calibrated p 0.028 ✓ | 9.8 EB05 8.3 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=111 · ♀ 0% (drug 67%) · 100% clinician | no trial arm names this drug |
| Nephrogenic anaemia | 282 | 9.8 8.7–11.1ROR 9.9 · calibrated p 0.034 ✓ | 9.2 EB05 8.3 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=282 | no trial arm names this drug |
| Multiple drug overdose | 295 | 9.5 8.5–10.7ROR 9.6 · calibrated p 0.038 ✓ | 9.0 EB05 8.1 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=294 · 100% clinician | no trial arm names this drug |
| Small for dates baby | 287 | 9.4 8.3–10.5ROR 9.4 · calibrated p 0.041 ✓ | 8.8 EB05 8.0 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=287 · ♀ 47% (drug 67%) | no trial arm names this drug |
| Long qt syndrome | 138 | 9.3 7.8–11.1ROR 9.3 · calibrated p 0.042 ✓ | 8.7 EB05 7.5 · IC025 +2.8 3/3 methods agree | Labeled — boxed warning exact term | serious n=137 · ♀ 100% (drug 67%) · 100% clinician | no trial arm names this drug |
| Multiple drug overdose intentional | 183 | 9.1 7.8–10.6ROR 9.1 · calibrated p 0.045 ✓ | 8.5 EB05 7.5 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=182 · 100% clinician | no trial arm names this drug |
| Hyperparathyroidism secondary | 142 | 9.1 7.7–10.8ROR 9.1 · calibrated p 0.045 ✓ | 8.5 EB05 7.4 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=142 | no trial arm names this drug |
| Blood pressure systolic abnormal | 139 | 9.1 7.6–10.7ROR 9.1 · calibrated p 0.046 ✓ | 8.4 EB05 7.3 · IC025 +2.8 3/3 methods agree | Lab value / disease marker | serious n=133 · ♀ 100% (drug 67%) · 100% clinician | no trial arm names this drug |
| Foetal death | 289 | 9.0 8.0–10.2ROR 9.1 · calibrated p 0.046 ✓ | 8.5 EB05 7.7 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=289 · ♀ 100% (drug 67%) · 100% clinician | no trial arm names this drug |
| Hyperreflexia | 191 | 8.8 7.6–10.2ROR 8.9 · calibrated p 0.049 ✓ | 8.3 EB05 7.3 · IC025 +2.8 3/3 methods agree | Labeled adverse reaction exact term | serious n=188 · 100% clinician | no trial arm names this drug |
| Bruxism | 294 | 8.8 7.8–9.9ROR 8.8 · calibrated p 0.049 ✓ | 8.3 EB05 7.5 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=265 | no trial arm names this drug |
| Completed suicide (death by suicide) | 4,402 | 8.5 8.2–8.7ROR 8.7 · calibrated p 0.051 | 8.1 EB05 7.9 · IC025 +3.0 3/3 methods agree | Outcome field, not a reaction boxed warning mentions mortality | age-adj. PRR 6.5 · serious PRR 6.0 · 94% clinician | no trial arm names this drug |
| Obsessive-compulsive disorder | 411 | 8.2 7.4–9.1ROR 8.2 · calibrated p 0.061 | 7.8 EB05 7.2 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=380 · ♀ 37% (drug 67%) | no trial arm names this drug |
| Torsade de pointes | 400 | 8.2 7.4–9.1ROR 8.2 · calibrated p 0.061 | 7.8 EB05 7.2 · IC025 +2.8 3/3 methods agree | Labeled — boxed warning exact term | serious PRR 5.8 · 100% clinician | no trial arm names this drug |
| Coeliac disease | 496 | 8.2 7.5–8.9ROR 8.2 · calibrated p 0.063 | 7.7 EB05 7.2 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious PRR 7.1 · ♀ 100% (drug 67%) | no trial arm names this drug |
| Atrial tachycardia | 106 | 8.1 6.7–9.9ROR 8.1 · calibrated p 0.066 | 7.6 EB05 6.4 · IC025 +2.6 3/3 methods agree | Labeled (related wording) related wording | serious n=106 · ♀ 100% (drug 67%) · 100% clinician | no trial arm names this drug |
| Blood pressure diastolic abnormal | 129 | 8.1 6.8–9.7ROR 8.1 · calibrated p 0.066 | 7.6 EB05 6.5 · IC025 +2.6 3/3 methods agree | Lab value / disease marker | serious n=125 · ♀ 100% (drug 67%) · 100% clinician | no trial arm names this drug |
| Alcohol interaction | 97 | 8.0 6.5–9.8ROR 8.0 · calibrated p 0.069 | 7.5 EB05 6.3 · IC025 +2.6 3/3 methods agree | Labeled (related wording) related wording | serious n=93 · ♀ 0% (drug 67%) · 100% clinician | no trial arm names this drug |
| Tachyphrenia | 170 | 7.9 6.8–9.2ROR 7.9 · calibrated p 0.070 | 7.4 EB05 6.5 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | serious n=135 | no trial arm names this drug |
| Bursitis | 586 | 7.8 7.2–8.5ROR 7.9 · calibrated p 0.071 | 7.5 EB05 7.0 · IC025 +2.8 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 6.3 · ♀ 93% (drug 67%) | no trial arm names this drug |
| Rebound acid hypersecretion | 146 | 7.7 6.5–9.0ROR 7.7 · calibrated p 0.078 | 7.2 EB05 6.3 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | serious n=146 | no trial arm names this drug |
| Electrocardiogram qt prolonged | 1,712 | 7.7 7.3–8.0ROR 7.7 · calibrated p 0.074 | 7.3 EB05 7.0 · IC025 +2.8 3/3 methods agree | Labeled (related wording) related wording | age-adj. PRR 6.6 · serious PRR 5.5 · 92% clinician | no trial arm names this drug |
| Dyslipidaemia | 236 | 7.5 6.5–8.5ROR 7.5 · calibrated p 0.083 | 7.1 EB05 6.3 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | serious n=229 | no trial arm names this drug |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Suicidality | 9,161 | 5.95.8–6.1 | signal |
| Hyponatraemia | 2,245 | 4.44.2–4.6 | signal |
| Depression | 6,360 | 3.53.5–3.6 | signal |
| Extrapyramidal | 2,307 | 3.43.3–3.6 | signal |
| Arrhythmia / qt | 3,560 | 2.92.8–3.0 | signal |
| Fall / fracture | 6,077 | 2.52.4–2.5 | signal |
| Gi bleeding | 2,488 | 2.12.0–2.2 | signal |
| Seizure | 2,504 | 2.01.9–2.1 | raised |
| Rhabdomyolysis / myopathy | 980 | 1.91.8–2.0 | raised |
| Pancreatitis | 899 | 1.71.6–1.8 | raised |
| Hypoglycaemia | 1,020 | 1.61.5–1.8 | raised |
| Kidney injury | 4,767 | 1.61.6–1.7 | raised |
| Anaemia | 3,052 | 1.61.5–1.6 | raised |
| Venous thromboembolism | 2,146 | 1.51.5–1.6 | raised |
| Serious infection | 7,357 | 1.51.4–1.5 | raised |
| Liver injury | 2,831 | 1.51.4–1.5 | raised |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Fatigue (tiredness) | 9,113 | 1.8 1.8–1.9ROR 1.9 · calibrated p 0.875 | 1.8 EB05 1.8 · IC025 +0.8 | Labeled adverse reaction exact term | age-adj. PRR 1.6 · serious PRR 1.9 | no trial arm names this drug |
| Nausea | 8,343 | 1.6 1.6–1.7ROR 1.7 · calibrated p 0.756 | 1.6 EB05 1.6 · IC025 +0.7 | Labeled adverse reaction exact term | age-adj. PRR 1.4 · serious PRR 1.7 | no trial arm names this drug |
| Drug ineffective (drug did not work) | 7,439 | 0.9 0.9–0.9ROR 0.9 · calibrated p 0.220 | 0.9 EB05 0.9 · IC025 -0.2 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | age-adj. PRR 0.9 · serious PRR 1.2 | no trial arm names this drug |
| Headache | 6,792 | 1.7 1.6–1.7ROR 1.7 · calibrated p 0.779 | 1.7 EB05 1.6 · IC025 +0.7 | Labeled adverse reaction exact term | age-adj. PRR 1.4 · serious PRR 1.9 | no trial arm names this drug |
| Diarrhoea (diarrhea) | 6,348 | 1.5 1.5–1.6ROR 1.6 · calibrated p 0.676 | 1.5 EB05 1.5 · IC025 +0.6 | Labeled adverse reaction exact term | age-adj. PRR 1.4 · serious PRR 1.4 | no trial arm names this drug |
| Pain | 6,024 | 1.5 1.5–1.6ROR 1.5 · calibrated p 0.666 | 1.5 EB05 1.5 · IC025 +0.6 | Labeled adverse reaction exact term | age-adj. PRR 1.5 · serious PRR 1.4 | no trial arm names this drug |
| Dizziness | 5,812 | 1.8 1.8–1.9ROR 1.8 · calibrated p 0.856 | 1.8 EB05 1.8 · IC025 +0.8 | Labeled adverse reaction exact term | age-adj. PRR 1.6 · serious PRR 1.9 | no trial arm names this drug |
| Fall | 5,710 | 2.7 2.6–2.7ROR 2.8 · calibrated p 0.713 | 2.6 EB05 2.6 · IC025 +1.4 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.4 · serious PRR 2.1 | no trial arm names this drug |
| Anxiety | 5,547 | 3.0 3.0–3.1ROR 3.1 · calibrated p 0.587 | 3.0 EB05 2.9 · IC025 +1.5 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.8 · serious PRR 2.8 | no trial arm names this drug |
| Dyspnoea (shortness of breath) | 5,421 | 1.5 1.4–1.5ROR 1.5 · calibrated p 0.643 | 1.5 EB05 1.4 · IC025 +0.5 | Labeled adverse reaction exact term | age-adj. PRR 1.3 · serious PRR 1.3 | no trial arm names this drug |
| Off label use (used outside approved label) | 5,335 | 0.9 0.9–1.0ROR 0.9 · calibrated p 0.271 | 0.9 EB05 0.9 · IC025 -0.1 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | age-adj. PRR 0.9 · serious PRR 1.0 | no trial arm names this drug |
| Depression | 5,275 | 3.6 3.5–3.7ROR 3.7 · calibrated p 0.433 | 3.6 EB05 3.5 · IC025 +1.8 3/3 methods agree | Labeled — boxed warning synonym match | age-adj. PRR 3.2 · serious PRR 3.1 | no trial arm names this drug |
| Toxicity to various agents | 5,191 | 4.9 4.8–5.0ROR 5.0 · calibrated p 0.230 | 4.8 EB05 4.7 · IC025 +2.2 3/3 methods agree | Not in label — unassessed | age-adj. PRR 4.6 · serious PRR 3.6 · 93% clinician | no trial arm names this drug |
| Vomiting | 5,062 | 1.7 1.6–1.7ROR 1.7 · calibrated p 0.768 | 1.7 EB05 1.6 · IC025 +0.7 | Labeled adverse reaction exact term | age-adj. PRR 1.5 · serious PRR 1.5 | no trial arm names this drug |
| Drug interaction | 4,447 | 4.4 4.3–4.5ROR 4.5 · calibrated p 0.292 | 4.3 EB05 4.2 · IC025 +2.1 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 3.9 · serious PRR 3.4 | no trial arm names this drug |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Temperature regulation disorder — n=556, PRR 52.5
- Agitation neonatal — n=130, PRR 24.2
- Disinhibition — n=216, PRR 23.7
- Respiratory disorder neonatal — n=204, PRR 22.6
- Catarrh — n=102, PRR 19.9
- Psychiatric decompensation — n=191, PRR 16.6
- Accidental death — n=153, PRR 13.8
- Food allergy — n=602, PRR 13.3
- Tearfulness — n=312, PRR 11.9
- Alcohol poisoning — n=183, PRR 11.4
✓ A hand-written Bradford Hill causality assessment exists for this drug: Citalopram ↔ QT prolongation.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Citalopram?
In FDA FAERS, the most frequently co-reported reaction terms for Citalopram are fatigue, nausea, headache, diarrhoea, pain, dizziness. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Citalopram have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short- term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )] .
Do FAERS signals prove that Citalopram causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 04766f1d-7a69-49ed-8fd3-1a6305505d47, effective 20260204; matched on
openfda.generic_name.exact:"CITALOPRAM" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,167 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
CITALOPRAM, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.